III. 5. Consolidation Phase

Consolidation is a months-long settling process in which diet, sleep, and stress matter as much to a lasting result as the donor preparation itself.

From Seeding to Settlement – The Biology of Consolidation

The consolidation phase begins where the induction phase ends: the donor microbial community has been introduced into the recipient gut in sufficient density to displace or suppress the dominant dysbiotic populations, and the first ecological turbulence of the initial days is subsiding. What follows is not passive recovery but an active, months-long process of ecological integration that determines whether the transplant will produce lasting change or gradually fade. Understanding this process – and the patient's active role within it – is the central purpose of this chapter.

Microbial ecological succession in the gut after FMT follows a pattern that ecologists recognize across all disturbed ecosystems: pioneer species establish first, modifying the environment in ways that favor or exclude subsequent colonizers; intermediate communities form and compete; and over weeks to months, a climax community emerges that is more stable and metabolically integrated than the initial pioneer assemblage [55], [34]. In the FMT context, the induction phase seeds the pioneer community. The consolidation phase is where intermediate-to-climax succession takes place. The outcome of this succession – the final composition and functional capacity of the stabilized community – is influenced not only by the donor preparation but by the environment the recipient provides: diet, sleep, physical activity, stress, medication profile, and the behavioral patterns described across the rest of this guide.

The minimum consolidation transfer duration of 60 days for non-CDI conditions and 30 days for CDI (established in Chapter II.1) is not the end of the ecological process – it is the minimum supported transfer window that substantially improves the probability of durable engraftment. Beyond this minimum, the consolidation phase continues as long as clinical monitoring indicates ongoing benefit and incomplete stabilization. Phase transition to step-down is a clinical decision, not an automatic calendar event.

Week by Week – The Consolidation Timeline

Weeks 2–3: Immune tolerance development and niche filling. The dominant biological process of the second and third weeks is the progressive development of mucosal immune tolerance to the donor microbial community. The gut's mucosal immune system – principally the lamina propria dendritic cells and regulatory T cell (Treg) populations – must distinguish the incoming donor taxa from potential pathogens and establish a tolerogenic rather than inflammatory response. This process is mediated by microbial metabolites, particularly short-chain fatty acids, which promote Treg differentiation and suppress effector T cell responses [56], [57]. Simultaneously, donor taxa are occupying ecological niches previously held by dysbiotic species: they compete for mucosal attachment sites, nutritional substrates, and spatial positioning along the crypt-villus axis. The outcome of this competition in weeks 2–3 largely determines the long-term community composition [34], [8].

Weeks 3–4: Metabolic integration and SCFA economy normalization. By weeks 3–4, in patients with favorable engraftment, stool SCFA profiles begin to stabilize at higher butyrate concentrations than pre-FMT baseline. This metabolic normalization has direct consequences for mucosal health: butyrate-driven colonocyte energy metabolism improves epithelial barrier integrity, reduces tight junction^[G] permeability, and supports the maintenance of the mucus layer [39]. Secondary bile acid profiles continue shifting toward an anti-inflammatory composition. Fecal calprotectin, if elevated in week 1, typically shows meaningful reduction by weeks 3–4 in responders, reflecting reduced mucosal inflammatory activity [54]. This is the window in which patients typically begin to report subjective improvement in energy, digestive comfort, and stool regularity – though the speed and magnitude of improvement vary substantially between individuals and conditions.

Weeks 4–6: Community maturation and behavioral reinforcement. The final weeks of the standard consolidation window represent ecological maturation: the stabilizing community increases in metabolic redundancy (multiple species performing overlapping functions, increasing resilience), interspecies mutualistic relationships deepen, and the community becomes progressively more resistant to perturbation. This is also the period in which lifestyle factors exert their greatest amplifying effect on FMT outcomes. The dietary fiber substrate, sleep regularity, physical activity level, and stress burden that the patient maintains during weeks 4–6 directly shape the ecological conditions into which the maturing community is integrating. A patient who maintains consistent dietary fiber intake during this period supports a nutritional environment that favors the dominant donor taxa; a patient who reverts to a highly processed, low-fiber diet removes the substrate advantage of those taxa and creates conditions that favor their gradual displacement by less demanding, dysbiosis-associated species [42], [58].

The Capsule Schedule During Consolidation – Rationale and Adherence

During the consolidation phase, capsule FMT is administered at moderate density (Phase 2 protocol: 2–5 times per week at prescribed dose) rather than at the high density of induction. This dosing rhythm is not arbitrary: it is designed to provide continuous low-level microbial reinforcement that prevents competitive rebound by residual dysbiotic species while allowing the maturing donor community to progressively integrate into the host ecosystem without the ecological stress of repeated high-dose exposure.

Why consistent timing matters. The gut microbiome follows circadian rhythms synchronized with host feeding and sleep patterns [59]. Capsule intake at consistent times of day – preferably after the main meal when intestinal motility and substrate availability are highest – aligns the incoming microbial inoculum with the periods of peak fermentative activity and mucosal turnover. Erratic dosing timing, while not catastrophic, reduces the ecological synchrony of the incoming community with host physiology and may reduce the efficiency of niche colonization. Patients are encouraged to take their consolidation capsules at the same time each day, integrated into a regular post-meal routine.

Managing missed doses. Single missed doses in the consolidation phase are unlikely to substantially compromise engraftment, as the donor community is already establishing multi-generational populations in the recipient gut by this point. However, consecutive missed doses (3 or more) create windows in which residual dysbiotic species can expand, particularly if dietary fiber intake is simultaneously low. If doses are missed for any reason, the patient should contact the clinical team rather than self-managing by doubling the next dose. Dose doubling without clinical guidance is not recommended and may exacerbate fermentative side effects.

Intercurrent illness and antibiotic courses during consolidation. Antibiotic courses required for intercurrent infections during the consolidation phase represent the most significant threat to engraftment continuity. If an antibiotic is prescribed during Phase 2, the clinical team should be notified immediately so that the FMT protocol can be adjusted: typically, capsule dosing is paused during the antibiotic course and for 48–72 hours afterward, then resumed. In some cases, a partial re-induction dose may be indicated after antibiotic exposure, depending on the agent used and the duration of treatment. This decision is always made by the clinical team, not self-managed.

Strain-level engraftment (2024). Aggarwala et al. 2024 (Cell Host & Microbe) established a precise strain-level measurement framework for post-FMT monitoring: a median of 41 donor strains stably engraft per recipient at 6 months. Strain-level engraftment of butyrate-producing Lachnospiraceae and Faecalibacterium prausnitzii predicts clinical response (AUC 0.81) — meaning shotgun metagenomic tracking at weeks 4–8 provides meaningful prognostic information [412].

Consolidation Phase Progress Monitoring

Table 7 – Consolidation phase weekly progression guide # Expected experiences are approximate and represent typical trajectories; individual variation is substantial. Patients not following the expected progression should contact their clinical team for assessment rather than self-adjusting the protocol.

The Patient's Active Role in Consolidation – Why Lifestyle Is Not Optional

A critical misconception about FMT is that the treatment is something done to the patient, after which the patient passively waits for results. The consolidation phase makes explicit what the entire protocol is designed around: the patient is an active ecological participant, not a passive recipient. The donor microbial community is introduced as a seed population, but whether it thrives, stabilizes, and produces durable clinical benefit depends on the environment the patient's daily choices create.

Dietary fiber as ecological infrastructure. The single most important lifestyle variable during consolidation is dietary fiber. Fermentable fiber is the primary energy source for the donor community; without consistent substrate supply, butyrate-producing taxa lose their competitive metabolic advantage and are progressively outcompeted by species better adapted to the host's nutritional environment [42], [58]. During weeks 2–6, the transition from the conservative Version B diet of the first week (see Chapter III.1) to the full fiber-optimized Version A diet should be made gradually: introducing one new fiber-containing food category every 3–5 days, monitoring tolerance in the diary, and expanding diversity as far as individual tolerance allows. By week 4, most patients should be tolerating legumes, raw vegetables, and prebiotic-rich foods (onion, garlic, chicory) with manageable fermentative symptoms.

Sleep and circadian alignment. Circadian disruption directly affects the gut microbiome's daily oscillation patterns [59]. During consolidation, the maturing donor community is synchronizing its metabolic rhythms with host feeding, sleep, and light-dark cycles. Irregular sleep timing, night-shift work, or severe sleep deprivation during this period disrupts this synchronization and is associated with reduced microbial diversity and impaired SCFA production in controlled human studies [60]. Patients in the consolidation phase are strongly encouraged to maintain consistent sleep and wake times (within 30 minutes day to day), to avoid significant social jet lag (weekend sleep pattern shifts), and to address sleep disorders with their physician if relevant.

Physical activity. Moderate aerobic exercise – particularly Zone 2 training (sustained moderate intensity, conversational pace, 30–45 minutes, 3–5 times per week) – is associated with increased microbial diversity, higher butyrate production, and improved colonization resistance in multiple human trials [61], [62]. The consolidation phase is the appropriate window to gradually reintroduce regular physical activity if it was reduced during the first week. Starting from week 2, daily walks of 20–30 minutes are appropriate for all patients. By week 3–4, Zone 2 aerobic exercise can be introduced in patients without cardiovascular or musculoskeletal contraindications. Heavy resistance training or high-intensity interval training should be approached carefully, as intense exercise transiently increases intestinal permeability; this is not contraindicated but should be introduced gradually.

Stress management. Chronic psychological stress dysregulates the gut-brain axis through multiple pathways: elevated cortisol alters intestinal motility and increases epithelial permeability; catecholamine signaling directly affects bacterial gene expression; and stress-driven behavioral changes (sleep disruption, dietary deterioration, alcohol use) create compounding negative ecological effects [53]. Patients in the consolidation phase who are experiencing significant life stressors should discuss this with their clinical team, as stress management support – including cognitive behavioral approaches or mindfulness practices – can be integrated into the treatment plan. The gut-brain axis effects described in Chapter VI of this guide are directly relevant to FMT consolidation outcomes.

Recognizing Progress – and When to Seek Review

Consolidation progress is not always linear. Patients may experience good weeks followed by symptomatic setbacks, particularly when dietary changes, stressful events, intercurrent illness, or disrupted sleep occur. These fluctuations are expected and do not indicate treatment failure: ecological systems are inherently dynamic, and temporary perturbations that are followed by return to the improving baseline are part of normal consolidation. What the clinical team looks for at end-of-phase review is the overall trend across the 4–6 week period, not individual day-to-day variation.

Patients should seek clinical review during the consolidation phase – between scheduled appointments – if any of the following occur: new onset of rectal bleeding; fever above 38°C; significant worsening of their underlying condition beyond the pre-FMT baseline that persists for more than 5 consecutive days; inability to maintain oral intake due to nausea or vomiting; or any of the acute warning signs listed in Chapter II.4. Minor symptom fluctuations that resolve within 1–3 days and are explainable by identifiable dietary or lifestyle triggers do not require unscheduled clinical contact but should be documented in the diary.

Microbiota Effects

• Progressive donor taxon engraftment continues throughout the consolidation phase: species-level donor representation in recipient stool typically increases from approximately 20–40% at day 7 to 40–70% by week 6 in favorable responders, with butyrate-producing Firmicutes taxa showing the most consistent and durable engraftment patterns [34], [8].
• Regulatory T cell (Treg) expansion in the intestinal lamina propria, driven by SCFA-mediated epigenetic modification of the Foxp3 locus, is the primary mechanism of progressive immune tolerance to the donor community; this process requires 2–4 weeks of sustained microbial exposure and is one of the principal biological arguments for extended consolidation over single-session FMT [56], [57].
• Fecal calprotectin, a marker of intestinal mucosal inflammation, typically follows a biphasic pattern after FMT: an initial transient elevation in week 1 (reflecting acute immune sampling of the new community) followed by progressive decline through weeks 2–6 in responders; persistent calprotectin elevation beyond week 4 may indicate incomplete mucosal immune tolerance and warrants clinical review [54].
• Secondary bile acid concentrations – deoxycholic acid and lithocholic acid – increase progressively through the consolidation phase as bile salt hydrolase-positive donor taxa establish and expand; these secondary bile acids reinforce colonization resistance against C. difficile and modulate host lipid metabolism and inflammatory signaling through farnesoid X receptor (FXR^[G]) and TGR5^[G] receptor pathways [39], [63].
• Microbial metabolic redundancy – the number of functionally distinct taxa performing each core metabolic function (fiber fermentation, amino acid synthesis, vitamin production) – increases through the consolidation phase, providing ecological resilience; higher redundancy is associated with greater resistance to perturbation and more durable long-term outcomes [55], [34].
• The gut–brain axis is progressively modulated during consolidation: tryptophan-serotonin pathway normalization, reduced lipopolysaccharide translocation across a strengthening epithelial barrier, and increased vagal afferent signaling from normalized SCFA production collectively contribute to the mood, energy, and cognitive improvements reported by a subset of patients in weeks 3–6 [53], [64].
• Dietary fiber intake during the consolidation phase directly amplifies engraftment: controlled crossover studies have demonstrated that high-fiber dietary conditions during the post-FMT window produce significantly higher proportional donor species representation and higher fecal SCFA concentrations compared to low-fiber conditions, confirming that the nutritional environment is a primary determinant of consolidation outcome [42], [58].

Patient Guidance

• Take your consolidation capsules at the same time each day, after your main meal. Set a phone reminder if needed. Consistency of timing amplifies the ecological synchrony of the incoming microbial community with your circadian physiology and improves the efficiency of niche colonization.
• From week 2, begin transitioning from the Version B (post-FMT first week) diet to the Version A fiber-optimized diet from Chapter III.1. Introduce one new fiber category every 3–5 days: start with cooked legumes (lentils, chickpeas), then add raw salad vegetables, then prebiotic-rich foods (onion, garlic, leek, chicory). Record your tolerance in your diary after each new introduction.
• By week 3, aim to resume light-to-moderate aerobic physical activity: 20–30 minute walks daily, or light cycling or swimming if preferred. By week 4–5, introduce Zone 2 aerobic training (30–45 minutes at conversational pace, 3–5 times per week) if you are medically cleared for this level of activity.
• Prioritize sleep consistency above all other lifestyle factors during the consolidation phase. Go to bed and wake at the same time every day, including weekends. Aim for 7–9 hours per night. If sleep quality is poor, discuss this with your clinical team – sleep disruption during this phase directly impairs microbial circadian rhythms and reduces SCFA production.
• Continue your Food and Symptom Diary every day throughout the consolidation phase. By week 2–3, the diary evolves from a post-procedure safety monitoring tool into a longitudinal progress tracker: use it to record not just symptoms but also positive changes – improvements in stool consistency, reductions in bloating, energy increases, and any improvements in your underlying condition symptoms.
• If you experience a symptomatic setback – worsening symptoms for 1–3 days after a dietary change, stressful event, or intercurrent illness – do not panic and do not adjust your capsule protocol independently. Document the trigger and the symptom change in your diary, maintain your usual dosing schedule, and monitor whether symptoms return to the improving baseline within 2–3 days. If they do not, contact your clinical team.
• Avoid alcohol during the consolidation phase if possible, particularly in weeks 2–4. Alcohol is a direct microbial disruptor that reduces Lactobacillus and butyrate-producing Firmicutes populations and increases intestinal permeability; its use during active ecological consolidation counteracts the FMT process. If complete abstinence is not feasible, limit intake to a maximum of 1–2 standard drinks per occasion, no more than twice per week.
• Do not start new over-the-counter supplements, herbal preparations, or commercial probiotics during the consolidation phase without first discussing them with your clinical team. Some supplements contain antimicrobial compounds (e.g., high-dose oregano oil, colloidal silver) that can suppress the donor community. Commercial probiotics contain different strains than the donor preparation and may compete with rather than support the engrafting community.
• If you must take antibiotics for any reason during the consolidation phase, contact your FMT clinical team on the same day. Do not wait. The clinical team will advise whether to pause capsule dosing during the antibiotic course, and whether a partial re-induction dose will be needed afterward. Early communication allows protocol adjustment that protects engraftment; delayed communication may result in significant ecological regression that requires extended recovery.
• At the end of the consolidation phase, prepare a summary of your diary data for the clinical review: note the overall trend in your key symptoms (stool pattern, energy, underlying condition), any significant setbacks and their apparent triggers, and your current dietary and activity level. This summary is the primary input for the clinical team’s decision on whether to transition to step-down or to extend the consolidation phase.

References

[8] Ianiro G, Punčochář M, Karcher N et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat Med. 2022. Link

Integrated shotgun metagenomic meta-analysis of 226 donor–recipient triads across eight disease types examining microbial engraftment dynamics after FMT. Higher donor strain engraftment was significantly associated with clinical success (P=0.017). Engraftment was greater with multi-route delivery (capsule plus colonoscopy) and in antibiotic-treated recipients with infectious disease versus antibiotic-naïve patients with noncommunicable disease. Bacteroidetes and Actinobacteria (including Bifidobacteria) showed higher engraftment than most Firmicutes. A cross-dataset machine-learning model predicted post-FMT species presence with AUROC 0.77.

[34] Smillie CS, Sauk J, Gevers D et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe. 2018. Link

Strain-level analysis of FMT for recurrent Clostridium difficile infection introducing Strain Finder, a method for inferring strain genotypes and tracking engraftment longitudinally. A statistical model predicted species-level engraftment largely from donor abundance and pre-FMT recipient phylogeny. Donor strains within a species engrafted in an all-or-nothing manner, and previously undetected strains frequently colonized recipients. The work defines the determinants of bacterial engraftment in human FMT and provides a framework for predicting graft outcomes.

[39] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link

Mechanistic review of short-chain fatty acids (SCFAs) — a major class of bacterial metabolites derived from dietary fibre fermentation — as central mediators between diet, gut microbiota, and host physiology. SCFAs activate G-protein-coupled receptors, inhibit histone deacetylases, and serve as energy substrates, thereby influencing metabolic, immune, and epigenetic processes. The authors synthesize evidence implicating SCFA-mediated signalling in both health maintenance and disease pathogenesis. Provides the conceptual backbone for fibre-based and microbiome-directed therapeutic strategies.

[42] Dahl WJ, Zhu H, Guan X. Dietary Fiber and Gut Microbiota in the Propagation of Short-Chain Fatty Acids. Am J Clin Nutr. 2023. Link

Analysis from the TEDDY observational cohort of 6,726 children at genetic risk for type 1 diabetes and celiac disease, evaluating whether dietary patterns by age 2 years contribute to celiac disease autoimmunity (CDA) and celiac disease independent of gluten intake. Children were annually screened for tissue transglutaminase autoantibodies (tTGA) from age 2. Principal component analysis extracted dietary patterns from 27 food groups assessed by 3-day food records at age 9–24 months. The study links specific early dietary patterns with CDA and celiac disease risk, suggesting modifiable nutritional exposures beyond gluten quantity.

[53] Cryan JF, O'Riordan KJ, Cowan CSM et al. The Microbiota-Gut-Brain Axis. Physiol Rev. 2019. Link

Review of free fatty acids (FFAs) — including dietary long- and medium-chain fatty acids and microbially produced short-chain fatty acids (SCFAs) — as ligands for free fatty acid receptors (FFARs), a group of G protein-coupled receptors linking metabolism and immunity. FFARs regulate inflammation, peptide hormone secretion, and host energy balance. The authors summarize FFAR pharmacology and its translational potential as a target for metabolic and inflammatory disease.

[54] Sokol H, Landman C, Seksik P et al. Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. Microbiome. 2020. Link

Randomized, single-blind, sham-controlled pilot trial of FMT in adults with colonic or ileo-colonic Crohn's disease in steroid-induced clinical remission. Patients were randomized at remission to receive FMT or sham transplantation during colonoscopy; corticosteroids were tapered and follow-up colonoscopy performed at week 6. The trial provides the first randomized data on FMT for maintaining remission in CD, with modest signals supporting microbial engraftment as a candidate driver of clinical response and informing larger confirmatory studies.

[55] Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science. 2009. Link

Spatial-temporal survey of the human microbiota sampling up to 27 body sites in 7–9 healthy adults on four occasions. Community composition was determined primarily by body habitat; within habitats, interpersonal variability was high while temporal variability within individuals was minimal. Skin locations harboured more diverse communities than gut and mouth and differed in community assembly patterns. The data establish baseline healthy biogeography of the human microbiota and a reference for disease-associated deviations.

[56] Arpaia N, Campbell C, Fan X et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013. Link

Mechanistic study showing that microbial metabolic by-products are sensed by host cells and modulate intestinal regulatory T cell (Treg) generation. The work links commensal microbial metabolism to gut immune homeostasis through Foxp3+ Treg cells, identifying microbial cues as drivers of anti-inflammatory T-cell differentiation. Findings establish a molecular bridge between diet, microbial metabolism, and mucosal immune regulation, supporting microbiome-targeted strategies for inflammatory disease.

[57] Furusawa Y, Obata Y, Fukuda S et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013. Link

Mechanistic study in mice showing that the SCFA butyrate, produced by Clostridia fermentation of dietary fibre, induces differentiation of colonic regulatory T (Treg) cells. NMR-based metabolomics showed luminal SCFA concentrations positively correlated with colonic Treg numbers. Butyrate acted via histone deacetylase inhibition on Foxp3 locus regulation. Identifies butyrate as a microbial mediator of mucosal immune tolerance and supports butyrate-augmenting interventions in inflammatory bowel disease.

[58] Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Martens EC, Schloss PD. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. mBio. 2019. Link

Two-week dietary intervention in 174 healthy young adults supplementing with resistant starch from potatoes (RPS), resistant starch from maize (RMS), inulin, or accessible corn-starch control. RPS produced the greatest increase in total SCFAs including butyrate. Most microbiomes responded to RPS with increased bifidobacteria, but responders with rising Ruminococcus bromii or Clostridium chartatabidum showed the highest butyrate concentrations. The study demonstrates substrate- and taxon-specific routes to butyrate enrichment, informing personalized prebiotic strategies.

[59] Thaiss CA, Zeevi D, Levy M et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell. 2014. Link

Mechanistic study in mice and humans demonstrating that the gut microbiota exhibits diurnal oscillations driven by feeding rhythms, producing time-specific compositional and functional profiles. Disruption of host molecular clock components or jet lag caused aberrant microbiota oscillations and dysbiosis through impaired feeding rhythmicity. Jet-lag-induced dysbiosis in both species promoted glucose intolerance and obesity that were transferable by FMT to germ-free recipients. Identifies microbiota–host circadian cross-regulation as a metabolic disease mechanism.

[60] Benedict C, Vogel H, Jonas W et al. Gut microbiota and glucometabolic alterations in response to recurrent partial sleep deprivation in normal-weight young individuals. Mol Metab. 2016. Link

Randomized within-subject crossover study in 9 normal-weight men comparing two nights of partial sleep deprivation (PSD; 02:45–07:00) with two nights of normal sleep (22:30–07:00) under standardized in-lab meal and exercise conditions. Faecal samples were collected and oral glucose tolerance was tested. The study assessed whether short-term sleep loss alters gut microbiota composition and metabolic function, providing early human evidence linking sleep restriction to acute microbiota shifts and insulin resistance.

[61] Estaki M, Pither J, Baumeister P et al. Cardiorespiratory fitness as a predictor of intestinal microbial diversity and distinct metagenomic functions. Microbiome. 2016. Link

High-throughput sequencing study in 39 healthy participants with similar age, BMI, and diets but varying cardiorespiratory fitness, with faecal SCFA quantification by gas chromatography. Peak oxygen uptake (VO2peak), the gold standard of cardiorespiratory fitness, accounted for more than 20\% of variation in microbial taxonomic richness independent of other factors including diet. VO2peak did not explain beta-diversity variation. The study links physical fitness with gut microbial alpha-diversity, supporting exercise as a microbiome-modulating intervention.

[62] Clarke SF, Murphy EF, O'Sullivan O et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014. Link

Cross-sectional 16S rRNA amplicon study comparing gut microbiota composition in professional rugby athletes with control groups matched for physical size, age and gender. Athletes showed higher microbial diversity and distinct community structure linked to both extreme exercise and accompanying dietary differences. Provides early evidence that elite-level exercise and diet jointly shape the gut microbiota, supporting downstream investigations into the exercise–diet–microbiome triad in metabolic and immune health.

[63] Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014. Link

Review of the bile acid–gut microbiome axis in health and disease, focusing on two major microbial pathways for bile salt degradation and the impact of bile acid composition on microbiota and host physiology. Bile acid pool size is now recognized as a function of microbial bile acid metabolism. Bile acids regulate the microbiome at the highest taxonomic levels and act as signalling hormones, with emerging evidence implicating them in liver carcinogenesis. The review frames bile acids as bidirectional mediators of host–microbiome crosstalk.

[64] Valles-Colomer M, Falony G, Darzi Y et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol. 2019. Link

Large-scale metagenomics study in the Flemish Gut Flora Project (n=1,054) with replication in independent datasets (total n=1,070) assessing correlations between microbiome features and host quality of life and depression. Butyrate-producing Faecalibacterium and Coprococcus were consistently associated with higher quality-of-life indicators, while Coprococcus and Dialister were depleted in depression independent of antidepressant use. The study provides population-scale evidence for a gut microbiota signature of mental health and depression.

[412] Aggarwala V, Mogno I, Li Z et al. Precise Quantification of Bacterial Strain Engraftment after FMT: A Strain-Level Tracking Framework. Cell Host \& Microbe. 2024. Link

In this commentary on Carasso et al., the authors highlight a study mapping invertible DNA elements in Bacteroidales genomes from IBD patients and healthy controls. Carasso et al. identified complex functional interactions involving Bacteroides fragilis, an invertible promoter, a capsular polysaccharide, a resident bacteriophage and the human host. These DNA inversions reversibly switch gene expression — including capsule synthesis and phage-related loci — and may modulate immune recognition in IBD. The commentary emphasizes the importance of integrating genomic and functional omics to characterize such regulatory elements and notes that systematic functional characterization across the gut microbiome is still incomplete.